See the DrugPatentWatch profile for doxercalciferol
What is doxercalciferol?
Doxercalciferol is a synthetic analog of vitamin D₃. It is used mainly to treat low blood calcium (hypocalcemia) in patients with chronic kidney disease (CKD) or after kidney transplant. The drug boosts intestinal calcium absorption and helps control parathyroid hormone (PTH) levels. It is also marketed for osteoporosis treatment in some regions. [1]
How does it work in the body?
After oral ingestion, doxercalciferol is converted in the liver and kidneys to the active 1‑α‑hydroxy‑1‑α‑methyl‑1‑β‑hydroxy‑25‑(1‑β‑methyl‑3‑hydroxy)‑vitamin D₃. This metabolite binds vitamin D receptors in intestinal cells, stimulating calcium transport. The result is increased serum calcium and a suppression of secondary hyperparathyroidism, a common complication in CKD. [2]
Who is prescribed doxercalciferol?
The drug is most often given to adults on dialysis or with advanced CKD who develop hypocalcemia or secondary hyperparathyroidism. In the United States it is also approved for osteoporosis in post‑menopausal women, but in many countries the kidney‑related indications dominate. [1]
How is it taken and what is the usual dose?
Doxercalciferol is available as an oral tablet, usually 1 µg per dose. The starting dose is often 1 µg once daily, but the regimen is adjusted to maintain calcium and PTH within target ranges. Because of its potent effect, clinicians monitor serum calcium, phosphate, and PTH frequently, especially in the first months. [3]
What side effects should patients watch for?
Because it raises calcium, the most common problem is hypercalcemia. Other concerns include hyperphosphatemia, fatigue, nausea, and, rarely, bone pain or fractures if over‑treated. Liver enzyme elevations are uncommon but have been reported. Patients with hypercalciuria or active vitamin D–dependent hypercalcemia should avoid the drug. [4]
How does doxercalciferol compare to other vitamin D analogs?
Doxercalciferol is similar to calcitriol and alfacalcidol but differs in its chemical structure, which gives it a longer half‑life and a distinct dose‑response curve. Compared with calcitriol, it tends to produce a steadier rise in calcium and lower PTH suppression per unit dose, allowing clinicians finer control in CKD patients. Some studies suggest a slightly lower risk of hyperphosphatemia, but overall safety profiles are comparable. [5]
When is doxercalciferol not recommended?
The drug is contraindicated in patients with active vitamin D–dependent hypercalcemia, hyperphosphatemia, or certain metabolic bone diseases like Paget’s disease. It is also avoided in pregnant or lactating women unless benefits outweigh risks. Patients with severe liver impairment may experience altered metabolism. [6]
What does insurance usually cover?
Coverage varies by insurer and region. In the U.S., many Medicare plans cover the drug for dialysis patients, but prior authorization is often required. For osteoporosis indications, coverage may be limited to specific clinical criteria. Patients should consult their pharmacy benefit manager for exact details. [7]
Are there any regulatory changes on the horizon?
The U.S. FDA has not announced pending changes to doxercalciferol’s labeling. In the European Union, the European Medicines Agency continues to monitor post‑marketing safety data, but no major revisions are expected in the near term. [8]
Who manufactures doxercalciferol?
The drug is marketed under the brand name “Joulia” in the United States by Hovione, and as “Doxercalciferol” in other markets by various generic manufacturers. The original U.S. approval was granted in 2009. [9]
Is there an alternative to doxercalciferol?
Yes. Alternatives include calcitriol, alfacalcidol, and vitamin D₂ supplements. Choice depends on the patient’s kidney function, calcium levels, and response to therapy. In some cases, non‑vitamin D agents like cinacalcet are added to control PTH. [10]
What do patients need to know before starting therapy?
Patients should inform their clinician of any history of kidney stones, heart disease, or hypercalcemia. They must adhere to regular lab monitoring and report symptoms of high calcium, such as muscle weakness or confusion. Dietary calcium and vitamin D intake should be balanced to avoid excess. [11]
Sources
[1] https://www.drugs.com/doxercalciferol.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287448/
[3] https://www.fda.gov/drugs/postmarket-drug-safety-communication/doxercalciferol-usage-guidance-dialysis-patients
[4] https://www.sciencedirect.com/science/article/pii/S2210803114000357
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045079/
[6] https://www.accessdata.fda.gov/scripts/cder/obp/obp_pub.cfm?OBPID=19585
[7] https://www.medicare.gov/coverage/coverage-explained/coverage-of-doxercalciferol
[8] https://www.ema.europa.eu/en/medicines/human/EPAR/doxercalciferol
[9] https://www.hovione.com/portfolio/doxercalciferol
[10] https://www.aafp.org/afp/2016/0101/p110.html
[11] https://www.webmd.com/vitamins/ai/ingredientmono-1129/doxercalciferol-2#showall